<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04854291</url>
  </required_header>
  <id_info>
    <org_study_id>PD-FMT</org_study_id>
    <nct_id>NCT04854291</nct_id>
  </id_info>
  <brief_title>A Trial of Fecal Microbiome Transplantation in Parkinson's Disease Patients</brief_title>
  <official_title>A Randomized, Double Blind, Placebo Controlled Multicenter Trial of Fecal Microbiome Transplantation Safety and Efficacy for Parkinson's Disease Patients With Abnormal Gut Microbiota Composition</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helsinki University Central Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Helsinki University Central Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      48 PD patients (age 35-75y; H&amp;Y 1-3) testing positive in a stool PD-dysbiosis test will be&#xD;
      randomized in a 2:1 ratio to receive either donor FMT or their own stool through intracaecal&#xD;
      infusion. The main outcome measure will be the sum of MDS-UPDRS I-III at 6 months to cover&#xD;
      motor and non-motor symptom changes. A wide array of secondary clinical outcome measures will&#xD;
      be assessed longitudinally and a large array of measurements, biospecimens (stool, urine,&#xD;
      blood, colonic biopsies), and imaging data will be collected for further analysis at&#xD;
      baseline, 1, 6, and 12 months.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 20, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of the sum of MDS-UPDRS I-III from baseline</measure>
    <time_frame>at 6 months post intervention</time_frame>
    <description>Sum of Movement Disorder Society Unified Parkinson's Disease Rating Scale sum of parts I, II, and III (in OFF state); Min 0 - Max 236 points (higher points indicating worse symptoms) will be determined at baseline and at 6 months after intervention. The difference between these values will be the primary outcome measure; Min 0 - Max 236 points (higher points indicating stronger improvement)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of MDS-UPDRS III from baseline</measure>
    <time_frame>at 6 months post intervention</time_frame>
    <description>Movement Disorder Society Unified Parkinson's Disease Rating Scale part III (in OFF state); Min 0 - Max 132 points (higher points indicating worse symptoms) will be determined at baseline and at 6 months after intervention. The difference between these values will be calculated; Min 0 - Max 132 points (higher points indicating stronger improvement)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of MDS-UPDRS IV from baseline</measure>
    <time_frame>at 6 months post intervention</time_frame>
    <description>Movement Disorder Society Unified Parkinson's Disease Rating Scale part IV; Min 0 - Max 132 points (higher points indicating worse symptoms) will be determined at baseline and at 6 months after intervention. The difference between these values will be calculated; Min 0 - Max 24 points (higher points indicating stronger improvement)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Timed UP GO test from baseline</measure>
    <time_frame>at 6 months post intervention</time_frame>
    <description>measured in seconds, higher value indicating worse clinical symptoms expressed as difference between 6 month post intervention and baseline, higher value indicating stronger improvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of MDS-UPDRS I from baseline</measure>
    <time_frame>at 6 months post intervention</time_frame>
    <description>Movement Disorder Society Unified Parkinson's Disease Rating Scale part I; Min 0 - Max 52 points (higher points indicating worse symptoms) will be determined at baseline and at 6 months after intervention. The difference between these values will be calculated; Min 0 - Max 52 points (higher points indicating stronger improvement)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of NMSS from baseline</measure>
    <time_frame>at 6 months post intervention</time_frame>
    <description>Non-motor symptom scale (0-360 points, higher points indicating worse symptoms) will be determined at baseline and at 6 months after intervention. The difference between these values will be calculated; Min 0 - Max 360 points (higher points indicating stronger improvement)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of MoCa from baseline</measure>
    <time_frame>at 6 months post intervention</time_frame>
    <description>MONTREAL COGNITIVE ASSESSMENT (0-30 points, higher points indicating less symptoms) will be determined at baseline and at 6 months after intervention. The difference between these values will be calculated; Min 0 - Max 30 points (higher increase indicating stronger improvement)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of BDI-II from baseline</measure>
    <time_frame>at 6 months post intervention</time_frame>
    <description>Beck Depression Inventory II (0-63 points, higher points indicating worse symptoms) will be determined at baseline and at 6 months after intervention. The difference between these values will be calculated; Min 0 - Max 63 points (larger decrease indicating stronger improvement)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of PDQ39 index from baseline</measure>
    <time_frame>at 6 months post intervention</time_frame>
    <description>Parkinson's Disease Questionnaire 39 index (0-100 points, higher points indicating worse quality of life) will be determined at baseline and at 6 months after intervention. The difference between these values will be calculated; Min 0 - Max 100 points (larger decrease indicating stronger improvement)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Donor FMT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FMT from a healthy donor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>NaCl + glycerol mixture (carrier solution of FMT arm)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Administration of donor FMT</intervention_name>
    <description>Intracaecal infusion of FMT</description>
    <arm_group_label>Donor FMT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Administration of placebo</intervention_name>
    <description>Intracaecal infusion of carrier solution</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of idiopathic PD (Clinically Probable PD)&#xD;
&#xD;
          -  H&amp;Y OFF 1-3 at Baseline Visit&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Chronic gastrointestinal disease (IBS allowed, celiac disease allowed if on gluten&#xD;
             free diet, gastritis allowed)&#xD;
&#xD;
          2. Any previous major gastrointestinal surgery that may alter gastrointestinal physiology&#xD;
&#xD;
          3. Any abdominal surgery in the last 3 months&#xD;
&#xD;
          4. Major genital and/or rectum prolapse&#xD;
&#xD;
          5. Active autoimmune disease&#xD;
&#xD;
          6. Active cancer within 5 years (allowed: basalioma and successfully removed carcinoma in&#xD;
             situ)&#xD;
&#xD;
          7. Immune deficiency&#xD;
&#xD;
          8. HIV infection&#xD;
&#xD;
          9. Antibiotic use in last 3 months before baseline visit&#xD;
&#xD;
         10. Dementia as indicated by Moca &lt;21p&#xD;
&#xD;
         11. Psychosis&#xD;
&#xD;
         12. Active significant impulse control disorder (by interview and medical records)&#xD;
&#xD;
         13. Major depression as indicated by BDI-II &gt;28&#xD;
&#xD;
         14. Pregnancy&#xD;
&#xD;
         15. Alcohol or drug abuse&#xD;
&#xD;
         16. Negative dysbiosis test result&#xD;
&#xD;
         17. Iodine allergy&#xD;
&#xD;
         18. Deep brain stimulation or Duodopa/Lecigon treatment&#xD;
&#xD;
         19. Inability to interrupt regular use of NSAIDs for at least one month before&#xD;
             permeability assessments&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Reeta Levo</last_name>
    <phone>00358504284113</phone>
    <email>reeta.levo@hus.fi</email>
  </overall_contact>
  <location>
    <facility>
      <name>Helsinki University Central Hospital</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reeta Levo</last_name>
      <email>reeta.levo@hus.fi</email>
    </contact>
    <investigator>
      <last_name>Filip Scheperjans, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Päijät-Häme Central Hospital</name>
      <address>
        <city>Lahti</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tampere University Hospital</name>
      <address>
        <city>Tampere</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Nevaharju</last_name>
      <email>Laura.Nevaharju@pshp.fi</email>
    </contact>
    <investigator>
      <last_name>Rebekka Ortiz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Turku University Hospital</name>
      <address>
        <city>Turku</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kari Lindholm</last_name>
      <email>Kari.Lindholm@tyks.fi</email>
    </contact>
    <investigator>
      <last_name>Valtteri Kaasinen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 13, 2021</study_first_submitted>
  <study_first_submitted_qc>April 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 22, 2021</study_first_posted>
  <last_update_submitted>April 17, 2021</last_update_submitted>
  <last_update_submitted_qc>April 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Helsinki University Central Hospital</investigator_affiliation>
    <investigator_full_name>Filip Scheperjans</investigator_full_name>
    <investigator_title>Adjunct Professor of Neurology</investigator_title>
  </responsible_party>
  <keyword>Parkinson's disease</keyword>
  <keyword>FMT</keyword>
  <keyword>microbiota</keyword>
  <keyword>gut-brain axis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

